APTSIS 20 target for a high-growth, high-profitability corporate group
First written in FY2016. 4 of 10 entries say "Restated". Latest entry: FY2021.
The whole theme swung hardest in 2021: 19 of 83 companies on the "Worse" side.
- FY2021SoftenedAnnual report
「Core operating profit reached ¥380 billion in fiscal 2017, but declined from fiscal 2018 onward due to the non-recognition of revenue from part of the royalty income from Gilenya in accordance with IFRS 15, following the commencement of arbitration proceedings in February 2019, as well as the impact of the US-China trade conflict and the COVID-19 pandemic.」
The fiscal 2020 targets under APTSIS20 were core operating profit of ¥174.7 billion, ROS of 5.4%, a loss attributable to owners of the parent of ¥7.6 billion, ROE of -0.6% and a net debt-to-equity ratio of 1.73, all substantially below target. The shortfall against the final-year target is explicitly presented as an actual result. - FY2020SoftenedAnnual report
「We are targeting core operating profit of ¥410 billion in the final year of APTSIS 20.」
While maintaining the final-year target of ¥410 billion, the main text and progress update explicitly state that, in light of the deterioration in financial metrics resulting from the US-China trade conflict, the COVID-19 pandemic and the acquisition of Tanabe Mitsubishi Pharma as a wholly owned subsidiary, “achieving the fiscal 2020 target will also be difficult.” - FY2019RestatedAnnual report
「“As the plan figures for the final year of APTSIS 20, we set fiscal 2020 targets of core operating income of ¥410 billion, ROS of 9%, profit for the year attributable to owners of the parent of ¥220 billion, ROE of 13% and a net D/E ratio of 1.0.”」
The company continues to state the fiscal 2020 targets revised in the previous filing. - FY2019-Q3RaisedAnnual report
「Based on progress under the plan through fiscal 2018, the company decided to revise the financial indicator targets for fiscal 2020, the final year, taking into account growth centered on the performance products segment through acceleration of the above measures, further realization of integration synergies, downside risks from market conditions in the Chemicals segment, and M&A and other activities in the Industrial Gases segment. Details of the revision Financial indicator Fiscal 2020 target (Initial target) Fiscal 2020 target (Revised) Core operating income ¥380 billion ¥410 billion ROS (core operating income margin on revenue) 8% 9% Profit for the year attributable to owners of the parent ¥180 billion ¥220 billion ROE (profit for the year attributable to owners of the parent divided by equity attributable to owners of the parent) 12% 13% Net D/E ratio (debt-to-equity ratio) (Note) 0.8 1.0」
For the fiscal 2020 targets under APTSIS 20, core operating income, ROS, profit for the year attributable to owners of the parent and ROE were raised to ¥410 billion, 9%, ¥220 billion and 13%, respectively. Meanwhile, the net D/E ratio was revised from 0.8 to 1.0, so the financial targets moved in different directions by indicator. - FY2018RaisedAnnual report
「In fiscal 2018, we will continue to pursue further transformation and growth, with a view to core operating income of ¥430 billion in the final year of “APTSIS 20.”」
In addition to the formal fiscal 2020 plan figure of ¥380 billion, the company has added wording indicating that it is targeting a higher level, with ¥430 billion in view for the final year. - FY2018-Q1RestatedAnnual report
「To achieve the five-year medium-term management plan “APTSIS 20,” covering the five years from April 2016, we integrated our three chemical operating companies, Mitsubishi Chemical Corporation, Mitsubishi Plastics, Inc. and Mitsubishi Rayon Co., Ltd., which were consolidated subsidiaries, effective 1 April 2017, in order to establish a structure capable of responding rapidly to changes in the management environment and making maximum use of management resources.」
The integration of 3 chemical companies is positioned as an initiative toward achieving APTSIS 20, and the basic policy of the medium-term plan remains unchanged. - FY2017RaisedAnnual report
「“APTSIS 20” final-year plan figures Financial indicators Fiscal 2020 Core operating income ¥380 billion ROS (core operating income margin on revenue) 8% Profit attributable to owners of the parent ¥180 billion ROE (return on equity attributable to owners of the parent) 12% Net D/E ratio (debt-to-equity ratio) 0.8」
The company restates the fiscal 2020 targets for APTSIS 20, with ROE raised from the previous target of at least 10% to 12%. - FY2017-Q3RestatedAnnual report
「Under the medium-term management plan “APTSIS 20,” our Group has adopted the fundamental policy of aiming to become a high-growth, high-profit corporate group through businesses in the performance products, materials and healthcare fields. Using core operating income, ROS, profit attributable to owners of the parent, ROE and the net D/E ratio as financial indicators, we will maintain an appropriate balance among investment in growth businesses, enhanced shareholder returns and strengthening our financial position, thereby working to enhance corporate value.」
The company continues to state the basic policy and financial indicators of APTSIS 20 and the balance among growth investment, shareholder returns and strengthening its financial position. - FY2017-Q1RestatedAnnual report
「Under the medium-term management plan “APTSIS 20,” our Group has adopted the fundamental policy of aiming to become a high-growth, high-profit corporate group through businesses in the performance products, materials and healthcare fields. Using core operating income, ROS, profit attributable to owners of the parent, ROE and the net D/E ratio as financial indicators, we will maintain an appropriate balance among investment in growth businesses, enhanced shareholder returns and strengthening our financial position, thereby working to enhance corporate value.」
The company restates the basic policy and financial indicators of APTSIS 20 and the balance among growth investment, shareholder returns and strengthening its financial position, but does not present new numerical targets. - FY2016First statedAnnual report
「“Under the basic policy of aiming to become a high-growth, high-profitability corporate group through businesses in the performance products, materials and healthcare fields, we established the following numerical targets for fiscal 2020 as financial indicators.”」
For fiscal 2020, the company set targets of core operating income of ¥380 billion, ROS of 8%, profit for the year attributable to owners of the parent of ¥180 billion, ROE of at least 10% and a net D/E ratio of 0.8.